Chuangyebang was informed that Shenzhen Xinyue Biotechnology Co., Ltd. (hereinafter referred to as “Xinyue Bio”) recently announced the completion of tens of millions of yuan in Pre-A round financing. This Pre-A round of financing was led by Bangqin Capital, followed by TusStar Ventures (Qirong Ventures) and Guocheng Dejun. The angel round investor Tongchuangweiye continued to increase its investment. In July last year, Xinyue Bio completed an angel round of financing led by Tongchuang Weiye and co-invested by Qianhai Innovation. The main purpose of this financing is to accelerate the construction of the DEL3.0 (DEL+AI) technology platform and the development of new drug pipelines, to meet a large number of unmet clinical needs in the fields of tumor immunity and other fields, and to achieve “empowering the development of new drugs with characteristic technologies and becoming a common citizen.” Affordable Good Medicine” vision.
Established in April 2021, Shenzhen Xinyue Biotechnology Co., Ltd. is the first biotechnology company incubated by the Guangdong Small Molecule New Drug Innovation Center. Relying on the DEL3.0 technology platform with independent intellectual property rights and unique live cell screening technology, Xinyue Biology focuses on the discovery, research and development and industrialization of FIC innovative drugs for unmet clinical needs, and is committed to becoming an international leading, A distinctive biotech company.
The core technical link of the innovative drug industry chain is new drug discovery. About one-third of the new drug development cost is used for new drug discovery and preclinical stages, which lasts five to six years. New drug development is characterized by high investment, high risk, and long cycle. The entire process from the discovery of new molecular entities to the launch of innovative drugs requires the synthesis and testing of a large number of compounds. New technical tools have become a key factor in changing the current status of new drug development.
DNA Encoded Library (DEL) technology is a new type of high-throughput drug screening technology that combines the advantages of combinatorial chemistry and high-throughput screening technology to efficiently find small molecules with high affinity to target proteins, which can greatly improve drug Probability of R&D success, reduce R&D costs, and shorten R&D cycle. The DEL 2.0 technology developed by Xinyue Biotechnology can be used for screening based on living cells. Compared with the biochemical model of the previous generation technology, the screening of DEL2.0 technology does not require the expression and purification of the target protein and is closer to the real environment in vivo, expanding the available screening methods. target range, while improving the success rate of new drug screening.
With the accumulation of drug research and development data and the rapid development of artificial intelligence technology (AI), the application of AI in new drug discovery is increasing, and its advantages have also been highlighted. Xinyue Bio’s DEL3.0 technology platform effectively combines DEL and AI to achieve complementarity. It can not only solve the problem of low quality of DNA coding database construction, but also solve the problem of lack of high-quality big data in AI technology, and the construction can be quickly updated. Iterative AI models significantly speed up the development of new drugs. The proof-of-concept work of the DEL3.0 platform has been completed, and the results have been formed into papers and accepted by high-level SCI journals.
Since its establishment more than a year ago, Xinyue Bio and the team of Professor Ding Ke of Jinan University have jointly developed a new generation of targeted anti-tumor drugs, and have reached new drug development cooperation with Lida Pilot and Nanjing Jingzhun to develop tumor immunotherapy drugs for new targets. The number of DEL3.0 targets that have been screened and to be screened has reached about 40, and an extremely rich pipeline has been reserved. Some projects have gratifying data and broad commercial prospects.
He Xun, founder and chairman of Xinyue Bio, said: “Thanks to the investors of this round, Bangqin Capital, Qirong Venture Capital, Guocheng Dejun and the old shareholder Tongchuang Weiye, for their support and trust in Xinyue Bio. Yue Bio’s DEL3.0 technology platform and pipeline layout are fully recognized. DEL+AI is likely to become the mainstream screening method in the field of small molecule new drug discovery. The company will continue to improve the DEL3.0 technology platform and develop DEL+PROTAC, DEL+ allosteric sites In the application field of DEL+X new combination scenarios such as drug development, we will promote the pipeline under development, actively carry out long-term cooperation with top domestic and foreign pharmaceutical companies and institutions, and use differentiated technologies to build a world-leading innovative drug company. We will support this financing. Continue to expand the R&D team, deepen the DEL3.0 technology mining, deploy and promote the project pipeline, and achieve new milestones.”
Dr. Liu Mingyu, founding partner of Bangqin Capital, said: “Bangqin Capital continues to pay attention to the breakthroughs brought by new technologies in the field of new drug research and development. Xinyue Bio is the first project led by Bangqin Capital in the field of innovative drugs. The Bangqin project team In the past six months or so, through many visits and exchanges, I have deeply understood the development layout of the entire industry. I believe that the business model of Xinyue Bio is unique in the industry. It not only has a technical tool for new drug screening, but also a steady stream of A development platform for generating original small molecule new drugs, through independent R&D and joint development of a dual-track-driven model, will have broader development space and rising potential in the future compared to traditional biotechnology companies.”
The person in charge of Tongchuangweiye Investment said: “Tongchuangweiye focuses on cutting-edge technological innovation, and invests in technological innovation enterprises that conform to national strategies and break through key technologies. The R&D team of Xinyue Biotechnology has built a world-leading DEL3.0 technology platform based on The platform technology is expected to cooperate with domestic and foreign pharmaceutical companies in the future, starting from Shenzhen, to serve the global new drug business.”
Wei Jiashen, managing director of Qirong Venture Capital, said: “Xinyue Bio has the underlying innovative technology, independent research and development and joint development project pipeline, new drug research and development industry chain research and development team and flexible business model, all of which have strengthened Qirong Venture Capital’s capital. With the confidence of this investment, Qirong Ventures will give full play to the synergy of investment and global network resources to provide Xinyue Bio with comprehensive and warmest post-investment value-added services, and work together.”
Tan Jiacheng, the executive partner of Guocheng Dejun, said: “Enterprises are the key players in technological innovation and the realization of high-level biotechnology self-reliance and self-improvement. We firmly believe that Xinyue Bio’s unique live cell screening DEL technology can truly serve China’s The empowerment of biotechnology development has brought new and revolutionary leaps, which will truly benefit the industry and patients, improve human health, and play a positive role in promoting technological progress in the biomedical industry and consolidating the core competitiveness of the pharmaceutical industry. Leading and exemplary role.”
attached
For more project information, please go to ” Analysis of Rui Beast “.
media coverage
Yiou investment community entrepreneurial state
Related events
- “Xinyue Bio” announced the completion of tens of millions of yuan in Pre-A round of financing, and Bangqin Capital led the investment2022-07-08
- Development and Reform Commission: Further increase support for the listing of biological enterprises in the domestic capital market2022-05-10
- Xianweida completed 450 million yuan in Series C financing, led by IDG Capital2021-10-12
- Highgrade Biotech completed USD 75 million in Series D financing to accelerate the advancement of innovative pipeline varieties2021-06-15
- Chen’an Biotech completed 70 million yuan in Series B financing2020-06-24
This article is reproduced from: https://readhub.cn/topic/8htDlG9Vfft
This site is for inclusion only, and the copyright belongs to the original author.